323 related articles for article (PubMed ID: 24092826)
1. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
An Z; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
3. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
Cordiner RLM; Mari A; Tura A; Pearson ER
J Clin Endocrinol Metab; 2021 Jun; 106(7):2036-2046. PubMed ID: 33693776
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Incretin Hormones After Orthotopic Liver Transplantation.
Gámán G; Sárváry E; Gelley F; Doros A; Görög D; Fehérvári I; Kóbori L; Wágner L; Máthé Z; Nemes B
Transplant Proc; 2015 Sep; 47(7):2207-9. PubMed ID: 26361681
[TBL] [Abstract][Full Text] [Related]
6. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected].
Juhl CB; Bradley U; Holst JJ; Leslie RD; Yderstraede KB; Hunter S;
Diabet Med; 2014 Aug; 31(8):941-5. PubMed ID: 24628669
[TBL] [Abstract][Full Text] [Related]
7. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
8. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
Muscelli E; Mari A; Casolaro A; Camastra S; Seghieri G; Gastaldelli A; Holst JJ; Ferrannini E
Diabetes; 2008 May; 57(5):1340-8. PubMed ID: 18162504
[TBL] [Abstract][Full Text] [Related]
9. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
[TBL] [Abstract][Full Text] [Related]
10. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
[TBL] [Abstract][Full Text] [Related]
11. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
12. Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
Perreault L; Man CD; Hunerdosse DM; Cobelli C; Bergman BC
Diabetes Res Clin Pract; 2010 Oct; 90(1):87-94. PubMed ID: 20708814
[TBL] [Abstract][Full Text] [Related]
13. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
14. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
Korish AA
Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
[TBL] [Abstract][Full Text] [Related]
15. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
[TBL] [Abstract][Full Text] [Related]
16. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
17. Impaired regulation of the incretin effect in patients with type 2 diabetes.
Bagger JI; Knop FK; Lund A; Vestergaard H; Holst JJ; Vilsbøll T
J Clin Endocrinol Metab; 2011 Mar; 96(3):737-45. PubMed ID: 21252240
[TBL] [Abstract][Full Text] [Related]
18. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
[TBL] [Abstract][Full Text] [Related]
19. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.
Ohta A; Kato H; Murayama K; Hashimoto E; Murakami M; Nishine A; Ohshige T; Sada Y; Asai S; Kawata T; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2014; 61(1):13-8. PubMed ID: 24064478
[TBL] [Abstract][Full Text] [Related]
20. The impact of diabetic autonomic neuropathy on the incretin effect.
Kazakos KA; Sarafidis PA; Yovos JG
Med Sci Monit; 2008 Apr; 14(4):CR213-20. PubMed ID: 18376350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
